In November, Trudy Oliver, PhD, professor of pharmacology and cancer biology at Duke University School of Medicine and Duke Cancer Institute, discussed the origins of small cell lung cancer (SCLC) and its impact on plasticity. Moderated by Dr. Misty Shields, Indiana University School of Medicine, and LUNGevity’s Ann Fish-Steagall, SVP of Patient Services and Health Care Delivery, this monthly virtual series highlights the latest discoveries and breakthroughs for SCLC.

Over the past twenty years, lung cancer research and care have entered a new era. One filled with hope, innovation, and progress that is transforming what it means to face a lung cancer diagnosis. From groundbreaking early detection efforts to life-extending treatments, each step forward represents years of collaboration between researchers, patients, and others in the lung cancer community. Today, LUNGevity celebrates five exciting areas of progress that highlight the incredible strides made through sustained lung cancer research. 1. The Precancer Genome Atlas: Stopping Lung Cancer Before It

In this Facebook Live on Tuesday, October 14, Toby Campbell, MD, MS, thoracic medical oncologist and chief of palliative care at the University of Wisconsin Health, discussed palliative care in small cell lung cancer. Moderated by Misty Shields, MD, PhD, IU Health, and LUNGevity’s Ann Fish-Steagall, RN, BSN, SVP of Patient Services and Health Care Delivery, the monthly Small Cell SMASHERS series highlights the latest discoveries and breakthroughs for SCLC.

In this Facebook Live from September 30, Sonam Puri, MD, Department of Thoracic Oncology at H. Lee Moffitt Cancer Center, discusses the importance of real-world data for treating small cell lung cancer. Moderated by Misty Shields, MD, PhD, IU Health, and LUNGevity’s Ann Fish-Steagall, RN, BSN, SVP of Patient Services and Health Care Delivery, the monthly Small Cell SMASHERS series highlights the latest discoveries and breakthroughs for SCLC.

As tobacco use has declined in recent years, we have seen a new demographic of lung cancer patients emerge. Lung cancer in individuals who have never smoked (LCINS) is becoming more common. These people are often younger women with no history of tobacco exposure. Researchers are working to understand the needs of this growing population by identifying other risk factors for lung cancer, such as family history and environmental exposures. They are also studying the molecular underpinnings of this disease to develop targeted approaches for early detection and treatment. As part of LUNGevity’s

Read time: 6 minutes. April turned out to be an exciting month for lung cancer science. First, we attended the 2025 Small Cell Lung Cancer (SCLC) Hot Topic Meeting held in New York from April 2-4, then the American Association for Cancer Research (AACR) Annual Meeting in Chicago from April 24-30. The SCLC Hot Topic Meeting, hosted by the International Association for the Study of Lung Cancer, has become one of our favorite science meetings. Held at the Memorial Sloan Kettering Cancer Center in New York, the meeting is one of a kind. It brings together scientists conducting preclinical research

The LUNGevity Conversations that Count speaker series offers an opportunity to stay informed, engage in critical discussions, and learn from top experts revolutionizing lung cancer care for underserved populations. The series is intended for healthcare professionals, community health equity champions, and anyone interested in equitable access to healthcare. In February, we welcomed Randi Williams, PhD, MPH, of the Lombardi Comprehensive Cancer Center at Georgetown University Medical Center. Her research focuses on methods to promote the adoption of evidence-based lung cancer control practices

On Friday, March 14, Christopher Kniese, MD, of IU Health, discussed the role of pulmonologists in SCLC, why the right diagnosis is key, logistics and importance of a bronchoscopy/biopsy, pulmonary rehab, and other topics. Moderated by Misty Shields, MD, IU Health, and LUNGevity’s Ann Fish-Steagall, SVP of Patient Services and Health Care Delivery, this monthly virtual series highlights the latest discoveries and breakthroughs in SCLC.

On Friday, February 28, Drs. and Rekhtman of Memorial Sloan Kettering Cancer Center joined us on Facebook Live to discuss the role of pathologists in SCLC, why the right diagnosis is key, and the logistics and importance of biopsies. They explained forms of SCLC such as atypical, transformed, and RB proficient. Moderated by Misty Shields, MD, PhD, IU Health, and LUNGevity’s Ann Fish-Steagall, SVP of Patient Services and Health Care Delivery, this monthly virtual series highlights the latest discoveries and breakthroughs in small cell lung cancer (SCLC).

Mya Tran, PharmD, BCOP, joined us in January to discuss what people should expect during treatment for small cell lung cancer (SCLC), managing side effects related to SCLC therapy, as well as the importance of genomics and its role in molecularly informed clinical trials for SCLC. Moderated by Dr. Misty Shields, IU Health, and LUNGevity’s Ann Fish-Steagall, SVP of Patient Services and Health Care Delivery, this monthly virtual series highlights the latest discoveries and breakthroughs in SCLC.